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Center's outgoing director believes today's 
research will yield key strides against cancer 
r 
Herbert Wotiz, Ph.D., outgoing director of 
the Hubert H. Humphrey Cancer Research 
Center, says his 40 years in cancer research 
have left him hopeful about ultimate vic-
tory but conscious that progress has proven 
slower than expected. 
The research community's record is 
narked by some major achievements, he 
notes. Childhood leukemia had a very 
high rate of mortality until chemo-
therapeutic treatments for it emerged in the 
1960s and 1970s. "Now," says Dr. Wotiz, 
"70 percent of the kids affected are saved." 
In his own area of interest—^breast can-
cer—there have been important advances, 
too. The drug tamoxifen, which blocks 
hormone action on cancer cells and so in-
hibits tumor growth, is another success 
story. 
Dr. Wotiz notes that he has had per-
sonal experience of the benefits such 
agents can bring. "I had a relative with 
metastatic breast cancer who was one of 
the early beneficiaries of tamoxifen," he 
notes. "She was treated with it, and lived a 
comfortable and productive life for 10 
years after being diagnosed with cancer." 
Dr. Wotiz concedes that, overall, 
progress against the disease—especially 
such common forms of it as lung and colon 
cancer—has been modest. Yet he's con-
vinced that the major advances being made 
in laboratories such as those of the 
Humphrey Cancer Research Center will 
;oon start having a major impact on cancer 
treatment. 
He notes that there have been key steps 
Herbert Wotiz, Ph.D., outgoing director 
of the Cancer Research Center, will 
remain involved with the Center's 
research activities. , .. , _ 
forward in the study of oncogenes—altered 
genes thought to be heavily involved in 
causing tumor growth. Important findings 
about the immune system and about special-
ized hormones like tumor necrosis factor 
(see story at right) also are encouraging, he 
says. Some of the recent discoveries being 
made in the laboratory, moreover, are al-
ready being put to use in caring for cancer 
patients, he notes. 
He believes, however, that some of the 
work now being done at the Cancer Center 
and its counterparts around the world will 
dwarf the contributions that modem biol-
ogy has made to cancer care up to now. He 
continued on page 2 
Researcher probes 
a hormone that 
destroys tumors 
An important achievement of biomedical 
research in recent years is the discovery 
of a hormone that can destroy certain 
tumors. 
The hormone, tumor necrosis factor 
(TNF), is a protein made by specific 
white blood cells. It was given its name 
after scientists found that, when added to 
tumor cells in the test-tube or admin-
istered to animals with cancer, it will kill 
off a variety of tumors. 
The discovery of TNF's effects on 
tumors initially stirred excitement among 
cancer researchers, says Deborah E. Dob-
son, Ph.D., a researcher at the Hubert H. 
Humphrey Cancer Research Center. Ef-
forts to use the hormone as an anti-cancer 
drug, though, have been impeded by the 
fact that TNF has multiple activities, 
some of which cause serious side effects. 
One effect is that TNF acts on normal 
fat and muscle tissue as well as on tumor 
cells. And that, in turn, reflects the 
ability of TNF to fight off invasions by 
tumor cells or microbes by mobilizing 
the energy that the body stores in the 
form of lipid (fat) inside fat cells. 
While that's obviously a useful role, it 
can be harmful if carried to extremes. In 
fact. Dr. Dobson says, it appears that 
that's what happens to many cancer 
patients. The body, in response to the 
continued presence of tumor cells, keeps 
on making TNF. The hormone, acting 
continued on page 3 
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Dr. Wotiz 
continued from page 1 
says, for example, that the studies of on-
cogenes and their counterparts, anti-on-
cogenes—genes that suppress both normal 
and abnormal cell growth—should lead to 
major inroads against the disease. "With 
any luck, we're going to see meaningful ap-
plications of the discoveries about on-
cogenes and anti-oncogenes within a very 
few years," he says. 
If in fact there is important further 
progress against cancer in the near future, it 
would mark a major change from the situa-
tion that existed when Dr. Wotiz entered 
the field. 
In 1950, having nearly completed his 
doctoral work in chemistry at Yale, he 
joined the Boston University School of 
Medicine. (The School had not founded 
the Cancer Center at that point.) He says 
he was delighted for the chance to conduct 
research on cancer. 
"My dad, though he wasn't a scientist, 
had read a lot about science, and he en-
couraged me to work on cancer," recalls 
Dr. Wotiz. "He recognized even then that 
biochemistry could have a major impact on 
our understanding of the disease." 
At the time Dr. Wotiz was launching his 
career, the treatment of cancer was charac-
terized by approaches that had little basis 
in scientific understanding. Though 
physicians knew, for example, that there 
was a connection between certain types of 
hormones and breast cancer, they didn't 
know which patients would benefit from 
what type of hormonal treatment. 
And that was not the only problem, says 
Dr. Wotiz. In the 1950s, many women 
were afraid to seek treatment. The reason, 
he says, was that cancer was regarded as a 
kind of curse or punishment, so that those 
who contracted the disease were often deep-
ly ashamed of the fact. 
Convinced that he could help improve 
the scientific basis for the treatment of can-
cer. Dr. Wotiz began what became a 
lifelong series of studies of the disease and 
related areas. Over the years, this work led 
to numerous contributions to our under-
standing of a range of issues, including 
how hormones work. His group showed, 
for example, that hormones such as 
estrogen and testosterone are not only al-
tered in the liver, as was known, but also in 
the organs that they act on. 
In later studies, the scientists showed 
that such hormones don't work effectively 
unless they're acting on a structurally com-
plete cell—a discovery linked with the find-
ings that eventually led to tests showing 
which breast cancer patients are likely to 
benefit from hormone-modifying treat-
ments like tamoxifen. 
While remaining active in research. Dr. 
Wotiz found himself increasingly involved 
in efforts to coordinate cancer research at 
the School of Medicine. "In the early 
1970s, there was an informal group of 
people involved in cancer work," he 
recalls. "We'd talk to each other about the 
problems that needed to be solved, but 
there was no organized cancer effort." 
That group, however, formed the 
nucleus of what is now the Hubert H. 
Humphrey Cancer Research Center. Set up 
in 1974, it has been headed since 1984 by 
Dr. Wotiz. 
High quality scientific work 
The outgoing director, who has seen the 
Cancer Center develop its capabilities in 
such emerging areas as the study of on-
cogenes, says it has been an exciting time 
to head the enterprise. Particularly reward-
ing, says Dr. Wotiz, has been the chance to 
work with the Center's young scientists, 
some of whom joined the Center during his 
tenure as director. "We've gotten very 
high marks for the quality of our scientific 
work," he says, "and the junior people in 
the Center have had a lot to do with that." 
Dr. Wotiz says he's delighted at the 
choice of his successor. Dr. Douglas Faller. 
He noted that the new director has the 
qualities needed to ensure that the Center 
continues to make important contributions 
to the struggle against cancer. "The fact 
that he's both a physician and a scientist is 
going to help keep the Cancer Center's 
scientific work closely tied in with patient 
care," says the outgoing director. 
Dr. Wotiz also praises the Center's 
financial supporters, saying that they have 
been and will continue to be critical to its 
success. "Without their backing," he notes, 
"we wouldn't have been able to make near-
ly as much progress as we have at this 
Center." 
As for himself, he says he hopes to 
remain involved in the field. In fact, it's 
more than a hope. The scientist notes that 
his former lab, which currently is directed 
by Dr. Abdul Traish, recently has produced 
monoclonal antibodies—immune-system 
molecules that all come from a single type 
of cell—that show promise of aiding in the 
diagnosis of breast cancer. 
Douglas V. Faller, MD., PhD. 
Physician-scientist 
named new director 
of Cancer Center _ ^ 
Douglas V. Faller, M.D., Ph.D., a 
physician-scientist who is deeply ex-
perienced in both patient care and research 
into the nature of cancer, is the new direc-
tor of the Hubert H. Humphrey Cancer Re-
search Center. 
Dr. Faller, previously a faculty member 
at Harvard Medical School and a senior 
staff member at Boston's Children's Hospi 
tal and the Dana-Farber Cancer Institute, 
was named to his new post by Aram V. 
Chobanian, M.D., dean of the Boston 
University School of Medicine. 
Dr. Faller's background includes a long 
history of treating both child and adult 
patients with cancer. Named vice chair-
man of the University Hospital's Division 
of Medicine as well as head of the Cancer 
Center, Dr. Faller says he plans to give 
high priority to enhancing the way cancer 
care is delivered. 
"I hope to simplify and facilitate the 
continuum of patient care as much as pos-
sible, so it is seen by the patient as loving 
and considerate," he says. The new direc-
tor also plans to give priority to cancer 
prevention, with outreach programs for the 
community neighboring Boston University 
Medical Center. 
As a scientist. Dr. Faller has made 
numerous contributions to our understand-
ing of how cancer emerges and spreads. 
Among his key discoveries is the fact that 
tumor-causing viruses have ways of dis-
arming a cell's own defenses, allowing the 
virus to reproduce itself more readily. 
Dr. Faller earned his Ph.D. in cancer 
viruses and cell biology at Massachusetts 
Institute of Technology, and received his 
medical training at Harvard. A complete 
profile of the new director will appear in 
the next issue of Humphrey Center News. 
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TNF protein 
continued from page 1 
^ike a traffic light that's always green. 
Keeps signaling fat cells to release energy 
untU all the lipid is used up. Then, TNF 
causes skeletal muscle cells to break 
down their proteins in order to continue 
to keep up with the body's energy 
demands. The result is a wasting condi-
tion called cachexia. 
Dr. Dobson says cachexia imposes a 
terrible burden on those affected. "They 
become very gaunt due to severe progres-
sive weight loss and they have no ener-
gy," she explains. 
Exploring effects on genes 
Although TNF's effects on healthy 
cells have limited its potential as a drug. 
Dr. Dobson says the hormone would still 
be useful if its activities in the body could 
be selectively manipulated. "You'd like 
it to keep on destroying tumor cells," she 
says, "but not let it attack healthy fat and 
muscle cells." 
Dr. Dobson is exploring the workings 
of fat and skeletal muscle cells, research 
that may set the stage for new treatments 
for both cachexia and cancer. Right now. 
Dr. Dobson's goal is to find out how TNF 
acts on these cells. She's doing so by 
studying its effects on certain genes. 
"There's a particular gene that's criti-
cal to the manufacture of lipids by fat and 
muscle cells," she says. "TTie idea is to 
figure out how TNF turns off genes like 
this. Then, we can ask, 'Okay, can we 
reverse this? Can we start the process of 
making lipids again?'" 
Dr. Dobson and her associates have 
made progress toward identifying the 
specific stretch of DNA that serves as the 
on-off switching point for this gene, 
glycerophosphate dehydrogenase (GPD). 
Once that goal is reached, the researchers 
will move on to studies of the mech-
anisms that relay the message from the 
blood-borne TNF to fat and muscle cell 
genes such as GPD. 
One question the reseachers ultimately 
want to help answer is whether it's pos-
sible to custom-design a new form of 
TNF. "Can we create a form of it," asks 
Dr. Dobson, "that acts on immune cells— 
because these cells 
attack tumors—^but 
not on fat or 
muscle cells?" 
The answer to 
that question is 
still a long way 
off. Still, Dr. Dob-
son says she feels 
privileged to be 
doing some of the 
work that eventual-
ly may provide it. 
"I really appreciate 
the Cancer Cen-
ter's support," she 
says. "Without 
that, we simply 
wouldn't have got-
ten very far at all." 
eborah E. Dobson, Ph.D., is investigating how the protein 
TNF affects fat and skeletal muscle cells. 
Tax Tips 
If you itemize your tax deductions, 
you can claim charitable gifts, like 
your gift to the Hubert H. 
Humphrey Cancer Research Center. 
You may also want to consider sup-
porting the Cancer Center through a 
planned gift. A planned gift 
benefits the Cancer Center and 
usually results in income and a 
charitable tax deduction for the 
donor. Planned gifts include: 
• Pooled Income Fund—similar 
to a mutual fund. Your gift 
provides an income, a charitable 
tax deduction, and avoids capital 
gains on a gift of appreciated 
securities. 
• Charitable Gift Annuity—a 
contract between the donor and 
the University that provides a 
stream of income and a 
charitable tax deduction. Best 
for donors age 70 and over. 
• Deferred Gift Annuity—similar 
to a charitable gift annuity ex-
cept that the payments are 
deferred to a future date. A great 
idea for donors age 30 to 55. 
Provides income at retirement 
and a charitable tax deduction 
today. 
• Appreciated Securities—a gift 
of appreciated securities 
provides you with a charitable 
tax deduction and avoids capital 
gains taxes. Most blue chip 
stocks pay a return of only two 
to four percent and if sold create 
capital gains or consequences. 
Your gift of securities to a 
charitable remainder trust or to 
the pooled income fund enables 
you to obtain a greater return, 
avoids capital gains taxes, and 
provides a charitable tax deduc-
tion. 
For more information on planned 
giving, please check off the planned 
giving box on the enclosed reply 
card and return it in the self-ad-
dressed envelope. 
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Cancer Center researcher leads studies of 
new therapy for chemotherapy-linked nausea 
Paul J. Hesketh, M.D., has had the 
pleasure of seeing his research efforts im-
prove the quality of life of many of his 
own cancer patients. In addition, he can 
look forward to the prospect of his work 
benefiting many thousands of such patients 
around the world. 
The experience grew out of Dr. 
Hesketh's lead role in a patient trial of a 
new drug, ondansetron, for the nausea 
caused by chemotherapy. The drug, says 
the Hubert H. Humphrey Cancer Research 
Center member, turned out to be highly ef-
fective in curbing such side effects. 
"We looked at the rate of emesis— 
vomiting—during the first 24 hours after 
patients started chemotherapy," he notes. 
"More than half the patients taking ondan-
setron had no emesis at all." 
Follow-up studies have shown that on-
dansetron works better and has fewer side 
effects than another anti-emetic currently 
in wide use. And Dr. Hesketh is now in-
volved in a major new study to see 
whether using ondansetron in combination 
with other drugs—a typical approach in 
dealing with chemotherapy-linked 
nausea—will boost the drug's effective-
ness still further. 
The effort to find better anti-nausea 
drugs reflects the fact that chemotherapy's 
benefits often come at a high cost in illness 
and discomfort. Nausea is one of the most 
serious of such side effects. "It's the thing 
that patients have heard about from friends 
and family members," says Dr. Hesketh, 
"and it's die thing they ask about the most." 
Medical science has developed a range 
of ways to treat such nausea. The use of 
combinations of agents has been especially 
effective. Still, problems remain. For one 
thing, some of the anti-nausea drugs in use 
have their own troublesome side effects. 
More serious is the fact that even combina-
tions of drugs don't work in all cases. 
"For at least a third of patients undergo-
ing chemotherapy," notes Dr. Hesketh, 
"emesis remains completely uncontrolled." 
In rare instances, the condition may be 
so bad that the patient affected drops out of 
treatment. "It can be a tragedy when that 
happens," says Dr. Hesketh, "especially 
when you're dealing with a highly curable 
condition like cancer of the testes." 
Among chemotherapeutic agents, the 
widely used drug cisplatin is one of the 
most likely to provoke nausea. Starting 
four years ago. Dr. Hesketh and his 
Humphrey Center associates, along with 
oncologists at other medical centers, began 
a patient trial of ondansetron's effective-
ness in curbing cisplatin-induced illness. 
Most of the 85 patients enrolled in the 
trial had either lung cancer or head-and-
neck cancer. They were given ondansetron 
starting just before they received their first 
dose of cisplatin. Then, their conditions 
were monitored over a 24-hour period—the 
critical span in terms of therapy-related 
nausea. 
Paul J. Hesketh, M.D., led trials of a 
drug that improves the quality of life for 
many cancer patients. 
Not only did the drug eliminate vomit-
ing for the majority of patients, but it also 
spared many of them any feelings of 
nausea. In addition, says Dr. Hesketh, 
there was less of the drowsiness that often 
accompanies standard anti-emetics. 
"The patients were alert, they were up 
and around, they were able to eat," he 
notes. "That could be very useful as we 
move more and more toward administer-
ing chemotherapy on an outpatient basis." 
The oncologist says it has been gratify-
ing to do work that is having such visible 
effects on the lives of many individuals. 
"This is a small step, but I believe a quite 
significant one in terms of improving the 
quality of life for patients undergoing 
chemotherapy," he notes. 
CANCER NOTES 
CANCER NOTE: New approaches to 
drug therapy use combinations of 
chemotherapeutic drugs, or chemotherapy 
plus surgery or radiation. New classes of 
agents are being tested for their effective-
ness in treating patients whose disease is 
resistant to drug therapies now in use. 
CANCER NOTE: A genetic fusing of can-
cer cells with normal cells can produce dis-
ease-fighting monoclonal antibodies 
(specific antibodies tailored to seek out 
chosen targets on cancer cells). Their poten-
tial in the diagnosis and treatment of cancer 
is under study. 
CANCER NOTE: Improvements in can-
cer treatment have made possible more con-
servative management of some early can-
cers. In early cancer of the larynx, many 
patients are now able to retain the larynx 
and voice; in colorectal cancer, fewer per-
manent colostomies are needed; and the 
surgery required in many cases of breast 
cancer is often more limited. 
CANCER NOTE: Hyperthermia is a way 
to increase the heat or temperature of the en-
tire body or a part of the body. It is known 
that heat can kill cancer cells. A cell 
temperature of 45° centigrade kills cancer 
cells. A temperature of 42° to 43° cen-
tigrade makes the cell more susceptible to 
damage by ionizing radiation (x-rays). 
Studies are under way to learn if hyperther-
mia can increase the effect of radiation 
chemotherapy. 
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